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Abstract 
As awareness of traumatic brain injury (TBI) increases, the need to detect mild forms and 
distinguish between the different severities of TBI becomes more apparent. The goal of this work 
is to develop a point-of-care sensor to detect whole blood biomarkers for rapid and sensitive 
diagnosis of TBI severity. Presented herein is the enzymatic detection of norepinephrine through 
the use of immobilization chemistry and impedance techniques. Sustained elevation of 
norepinephrine concentrations in the blood has been correlated to negative long-term outcomes 
in TBI cases, often resulting in permanent cognitive or physical deficits.  
 
Novel analysis techniques have been used to identify an optimal binding frequency (371.1 Hz) of 
norepinephrine to the immobilized enzyme on a gold disk electrode. This form of analysis 
yielded a logarithmic fit characterized by exceptional responsivity (20.89 ohms/pgmL
-1
), 
reproducibility (R
2
= 0.96), and lower limit of detection (98 pg/mL) first in purified samples, then 
in rabbit whole blood solutions. Once the optimal binding frequency was determined, the 
preliminary use of an impedance-time technique was attempted in this work. This technique 
more closely resembles the amperometric detection method used in commercial self-monitoring 
blood glucose meters, allowing for continuous or instantaneous measurement of blood borne 
biomarkers without compromising sensitivity. Future directions include exploration of 
simultaneous multi-marker detection with the impedance-time technique and experimentation 
with novel mesoporous materials to filter large blood components. 
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1. Introduction 
Each year 1.4 million and 1 million people in the United States and Europe, respectively, visit 
hospitals and urgent care centers to be treated for traumatic brain injury (TBI) (Brain Injury 
Facts, 2011; Faul et al., 2010). In 2010, the estimated costs associated with TBI were $76.5 
billion, averaging $45,000 per injury in the US (Finkelstein et al., 2006). Unfortunately, TBIs are 
easy to miss as 75% of TBIs are mild with little to no apparent symptoms, while multiple mild 
TBIs occurring in quick succession can cause life-altering brain damage or death (National 
Center for Injury Prevention and Control, 2003). Moreover, in mild and moderate injury cases, 
the brain will continue to sustain secondary damage during the extensive healing process which 
can be prolonged without treatment (National Hospital Discharge Survey, 2011). 
 
Today, several devices and methods exist to detect TBI. The most traditional method used 
clinically is the Glasgow Coma Scale (GCS) based on verbal, eye and motion responses which is 
often augmented with computer tomography imaging in moderate to severe cases (Svetlov et al., 
2010; Hergenroeder et al., 2008). Current devices to monitor head trauma include piezoelectric 
or acceleration sensors that line a helmet for military or contact sport use (Daniel et al., 2010; 
Greenwald et al., 2008). Other non-commercial devices are biosensors which measure TBI 
biomarkers in cerebral spinal fluid or blood (Svetlov et al., 2010). These biosensors are 
particularly useful in quantitatively diagnosing TBI severity, whereas the piezoelectric sensors 
do not yield any direct physiological information (Chamoun et al., 2009). However, as 
advantageous as these detection platforms may be, they are not yet portable nor are they 
continuous in physiological state detection (which could be advantageous in intensive care 
cases). 
 
Literature has shown that the catecholamines, including norepinephrine, have a positive 
correlation with trauma such as brain injury (Clifton et al., 1981; Mautes et al., 2001; Salim et 
al., 2009). Generally, asymptomatic levels of the catecholamines are 0 nM to 10 nM (0-1750 
pg/mL) in urine and 0.19 nM to 11 nM (33.25-1925 pg/mL) in blood (Kumar et al., 2011; Mayo 
Clinic Laboratories, 2012). As a result of trauma, catecholamine blood concentrations fluctuate 
and can reach levels of 29 nM (49 ng/mL) or higher, depending on severity (Hamill et al., 1987). 
However, the current method to measure catecholamine levels is conducted in clinical 
laboratories by high-performance liquid chromatography (HPLC) on blood or urine samples 
(Mayo Clinic Laboratories, 2012; Tsunoda et al., 2009). Other developed non-clinical methods 
of catecholamine detection include electrochemical techniques in conjunction with various 
nanosensors or coatings, and purification methods such as hydrophilic interaction 
chromatography (Atta et al., 2010; Kim et al., 2010; Kumar et al., 2011; Prasad et al., 2009). 
Disadvantages of these methods include the need for a clinical chemistry laboratory to conduct 
the assay, time and resource costs for sample transport, stabilizing reagents and purification steps 
(Atta et al., 2010; Kumar et al., 2011; Mayo Clinic Laboratories, 2012; Prasad et al., 2009). To 
be useful in situations where the symptoms are transient, catecholamine levels would need to be 
measured frequently and rapidly, even at the bedside, which current assay methods do not 
permit. Despite these drawbacks, these measurement methods have achieved sufficient lower 
limits of detection (LLD) to reach the physiological levels of catecholamines.  
 A promising electrochemical technique, often called the impedance-time technique, has been 
developed and used for a variety of purposes including monitoring cell proliferation on a surface 
and sensing DNA hybridization within 5-10 nM concentrations (Ghindilis et al., 2009; Upadhyay 
et al., 2000). The continuous-time and high sensitivity aspects of this technique bears striking 
similarities to the glucose meter’s amperometric technique which shows promise as a TBI point-
of-care diagnostic. As our understanding of TBI improves and as public and government concern 
regarding TBI rises in light of contact sport injuries and modern combat deaths, the need for a 
point-of-care technology to rapidly diagnose TBI has never been greater. To address this gap, 
this work explores impedance-based electrochemical techniques which have shown promise as 
point-of-care modalities with the sensitivity and specificity required to diagnose TBI in complex 
media. 
 
2. Material and Methods 
2.1 Chemical Reagents 
All chemical reagents were purchased form Sigma-Aldrich, St. Louis, MO, USA unless 
otherwise stated. Potassium hexacyanoferrate (III) was dissolved in 10 mM Phosphate Buffer 
Saline (EMD Chemicals, Billerica, MA, USA), henceforth called redox probe. 
Phenylethanolamine N-methyl transferase (PNMT) used in the electrochemical studies to detect 
Norepinephrine was purchased from Calzyme (Tulelake, CA, USA) and immobilized using 1 
mM 16-mercaptohexadecanoic acid (16-MHDA) in ethanol, 10 mM N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide (in PBS, henceforth called EDC), 80mM (in PBS) 
N-Hydroxysulfosuccinimide Sodium Salt, henceforth called NHS (Toronto Research Chemicals, 
Toronto, Ontario, Canada), and 1% (in DI) Ethanolamine. The DL-Norepinephrine 
Hydrochloride solutions with excess amounts of the PNMT co-factor, S-(5′-Adenosyl)-L-
methionine chloride dihydrochloride (SAM) were made into various concentrations ranging from 
5.9 pM to 59.1 nM (1-10,000 pg/mL) of NE in 10 mM PBS solution at pH 7.4. White New 
Zealand rabbit whole blood stabilized with K2-EDTA was purchased from Bioreclamation LLC 
(New York, USA).  
 
2.2 Electrochemical Cell 
The electrochemical cell included a 2 mm gold disk working electrode (GDE), a Ag/AgCl wire 
reference electrode, and a Platinum wire counter electrode (purchased form CH Instruments, 
Austin, TX, USA). The electrochemical cell was established by placing a trimmed 1 mL pipette 
tip onto the GDE and bending the Ag/AgCl electrode (d=0.5mm) and Pt electrode (d=0.5mm) 
wires into the cut pipette tip. Alligator clips connected the cell to the 660C CH Instruments 
Electrochemical Analyzer. The samples pipetted into the well were a mixture of PBS and/or 
whole rabbit blood, norepinephrine, and 100 mM ferricyanide redox probe. Prior to 
functionalization, cyclic voltammetry (6 segments, 1 to -1 V) was performed on clean GDEs 
using 100 µL sample of redox probe to determine the formal potential (average of oxidation and 
reduction peak voltages). 
 
2.3 Functionalization 
The process of preparing the GDE can be found in La Belle et al., 2013 and is illustrated in 
scheme 1, but is briefly described here: the GDE is cleaned using Al2O3 polishing pads and 
sonicated in DI water for 20 mins, then the alkane-thiol self-assembling monolayer (1 mM 16-
MHDA dissolved in ethanol) is incubated on the GDE surface for 1 hr. Next, a 10 mM EDC/80 
mM NHS in PBS solution is placed on the GDE surface for 1 hr to prepare the carboxyl end of 
the 16-MHDA for protein attachment. Then, the enzyme (0.01 mg of PNMT in 1 mL PBS) is 
incubated on the modified GDE surface for 1 hr. Finally, 1% ethanolamine in DI is incubated on 
the sensor surface for 30 mins to prevent non-specific binding on any remaining bare gold and 
unbound 16-MHDA. After functionalization, the GDEs were stored in PBS at 4 °C until the 
NE+SAM concentration gradients were run. 
 
Scheme 1. 
A schematic illustrating the immobilization chemistry process to functionalize the PNMT enzyme onto a GDE. 
Once functionalized, a solution containing SAM will activate the enzyme and allow NE binding to result in current 
production and impedance changes. 
 
2.4 Electrochemical Impedance Spectroscopy (EIS) 
The EIS method uses an AC voltage signal which changes frequency to stimulate the solution 
while current is being measured. Based on this measured current, impedance and phase are 
calculated in real-time, then plotted in the Nyquist graphs as shown in Fig1a. To achieve this, the 
following parameters were set: Initial E= formal potential found in the CV prior to 
functionalization, High Frequency= 100 kHz, Low Frequency= 1 Hz, and Amplitude= 5 mV. 
After the GDE is functionalized, a NE+SAM in PBS serial dilution gradient consisting of 10 
solutions ranging from 1-10,000 pg/mL (or 5.9 pM- 59.1 nM of NE) is run from lowest to 
highest concentration. These solutions encompass the entire physiological range  and include an 
excess amount of SAM co-factor in PBS. Each solution was 50 µL of NE+SAM in PBS mixture 
and 50 µL of 100 mM ferricyanide redox probe. 
 
For the rabbit whole blood experiments, the solutions had the same effective concentration of NE 
and SAM but were mixed into 5%, 10%, 25%, and 90% whole blood in PBS solutions. For 
example, the 10% whole blood solution tested was 25 µL of 200 mM ferricyanide, 25 µL of 4x 
NE+SAM in PBS solution used in the purified case, 10 µL of whole blood in 40 µL of PBS. The 
90% whole blood solution was 5 µL of 1000 mM ferricyanide, 5 µL of 20x NE+SAM in PBS 
solution used in the purified case, and 90 µL of whole blood. This data was obtained the same 
way as the purified data: a blank of only PBS and redox probe was first run, followed by the NE 
concentration gradient. 
 
2.5 Impedance-Time (Z-t) 
The Impedance-Time technique is similar to the EIS method. Instead of sweeping over a 
frequency range, only one frequency is applied over time. The resulting data is plotted as the 
complex impedance versus time as shown in Figs 2a and 2c. In the Z-t experiments, the 
following parameters were set: Initial E= formal potential found in the CV prior to 
functionalization, Amplitude= 5 mV, Frequency= any frequency of interest in Hz, Sample 
Interval= 1 sec, Run Time=  any time range in sec. The first set of Z-t experiments were run on 
the purified 1-10,000 pg/mL NE+SAM concentration gradient for 90 sec at 368 Hz. The second 
set of Z-t experiments were continuous impedance measurements as the initial sample of 50 µL 
of 100 mM ferricyanide was spiked with 500 pg/mL NE+SAM in PBS at 30, 40, 85, 145, and 
325 sec time points after initialization of the Z-t assay. 
 
3. Results and Discussion 
 
3.1 EIS Results 
Fig. 1a overlays the Nyquist curves for the blank (0 pg/mL), 1 pg/mL and 5,000 pg/mL 
NE+SAM solutions run using EIS (though all 10 solutions were run). The black curves indicate 
the purified NE+SAM solutions made using only PBS and the redox probe. The gray curves 
refer to the 10% whole blood data collected for the same effective NE+SAM concentrations. 
These data were fitted to the classical Randles Equivalent Circuit R(CR) model and found to 
have a χ2 ranging from 1.01E-02 to 1.42E-02 in the purified case and 3.94E-02 to 4.86E-02 in 
the 10% whole blood case, indicating that the impedance Nyquist curves closely resemble the 
Randles Model. The components of this Randles model include a solution resistance, an electron 
transfer resistance, and a double layer capacitor caused by the SAM which separates changes 
from the GDE. It is evident from these Nyquist curves that the blood solution yields a greater 
responsivity than the purified solutions. This is likely due to the larger proteins such as albumin a 
blood cells aggregating near the electrode surface. However, this does not prevent specific 
binding of NE to the PNMT enzyme as the impedance increases in a logarithmic fashion as a 
function of NE concentration. Fig. 1b shows the calibration curves for each solution case (pure 
and 10% whole blood) at the determined optimal frequency of 371.1 Hz. Ideally, a hand-held 
meter could be programed with these equations, and after running EIS on an unknown sample, 
this calibration curve could be used to convert the measured impedance into a concentration of 
NE in a complex media. Fig. 1c illustrates the challenge of selecting an optimal frequency. It is 
evident that the relationship between NE concentration and complex impedance is logarithmic, 
but there is a tradeoff between responsivity (slope) and reproducibility (R
2
) for these logarithmic 
fits. Fig. 1c shows an n=1 purified case, but after several PNMT immobilizations and NE+SAM 
gradients (N=12), 371.1 Hz was chosen as it consistently had an R
2
 > 0.95, comparatively 
consistent slopes around 20 ohms/pgmL
-1
, from which an LLD of 98 pg/mL (579 pM) of NE was 
determined. For the clinical standard HPLC detection mechanism, the lower ranges of detection 
are 0.5-2.5 ng/mL, whereas the ELISA method can detect concentrations of 10 pg/mL, while 
another novel modified electrode using a differential pulse voltammetry could detect 
catecholamines in the lower µM (80+ ng/mL) range (Atta et al., 2010; Raggi et al., 1999; 
Svetlov et al., 2010). However, these techniques may require filtering of samples (whereas the 
whole blood samples in this publication are merely diluted), require many hours of assay time, or 
requires time-consuming data analysis. Fig. 1d confirms the issue of complex media causing 
noise in the impedance signal at the optimal frequency of 371.1 Hz. The 5, 10 and 25% blood 
solutions seem to follow a logarithmic pattern, but the 90% whole blood solution becomes less 
predictable. However, this still shoes promise as a point-of-care technology. In a test strip form 
factor, the strip could contain some amount of PBS which will dilute the whole blood to an 
optimal percentage. This is feasible since head injury increases norepinephrine blood levels, the 
LLD should be sufficient to diagnose a head injury. 
 
 
 
Fig. 1. 
(a) Overlay of Nyquist curves resulting from impedance readings on 2 PNMT immobilized GDEs in purified (black) 
and 10% whole blood (gray) NE+SAM solutions. (b) Calibration curves plotting impedance as a function of NE 
concentration at the 371.1 Hz optimal binding frequency in purified (black) and 10% whole blood (gray) solutions. 
(c) This graph shows the relationship between a logarithmic fit R
2
 versus a logarithmic fit slope. In the case of 
PNMT and NE, there is a tradeoff between reproducibility and responsivity. (d) This is a comparison of logarithmic 
fit R
2
 (black) versus a logarithmic fit slope (gray) at 371.1 Hz as a function of % whole blood in the NE+SAM 
solution. 
 
3.2 Z-t Results 
The Z-t technique was attempted in an effort to reduce the required amount of hardware which 
would need to be miniaturized for a hand-held point-of-care technology. Additionally, this 
technique can be used to more thoroughly investigate and optimize the frequency selected for 
stimulation. Z-t applies only one frequency instead of several as in EIS, this can certainly be 
achieved without changing the detection mechanism or compromising sensitivity. 
 
Fig. 2a corresponds to the first set of data collected using Z-t. Each NE+SAM solution (1-10,000 
pg/mL) was run for 90 sec, the same amount of time for an EIS run. Both sets of data (black and 
gray) are similar GDEs experiencing the same solutions. However, there is a basal shift between 
the two theoretically same GDEs, and a slight basal shift as the concentration of NE increases. 
This is likely to be a temperature effect, observable after many consecutive runs. The total time 
of this data collection was over 45 minutes at room temperature, which is impressive from a 
stability standpoint. Additionally, the sensitivity increases as the resulting LLD= 8 pg/mL (47.29 
pM). This preliminary Z-t LLD is based on N=2 purified data while the EIS LLD is based on 
N=12 purified and whole blood data, but it shows promise for being as sensitive as a sandwich 
ELISA with a sensitivity of 10 pg/mL reported by Svetlov, et al (2010). However the Z-t method 
requires significantly less assay time; if the electrodes are prepared, quantification of a biomarker 
can be done in seconds. 
 
Fig. 2b shows the process of selecting an optimal time to collect the impedance data. According 
to these data, 3 sec after assay initialization provides a strong correlation to NE concentration. 
This is a key finding if a hand-held meter can be programmed to stimulate the solution with a 
371.1 Hz frequency, the solid black calibration equation could be used to convert impedance to 
NE concentration based on only 3 sec of data, rivaling commercial glucose meters. 
 
The last set of data collected with the Z-t technique explored different frequencies using 500 
pg/mL purified NE+SAM solutions for optimization purposes. Fig. 2c shows continuous spiking 
at the same intervals of PBS or 500 pg/mL NE+SAM solutions. There is an observable 
difference between the two applied frequencies, which is more significant than a small basal 
impedance difference. This solidifies our EIS findings that there is an optimal frequency at 
which analyte-protein binding occurs. As shown in Fig. 2d, the average (N=2) peak height 
corresponding to NE injections are more consistent at the 368 Hz frequency as opposed to the 
321 Hz frequency. Two other frequencies, 3676 and 46300 Hz, were also tested (data not shown) 
to determine if a harmonic relationship existed and to try a “dead” frequency. The 3676 Hz 
harmonic data showed no response to 500 pg/mL (2.96 nM) NE+SAM solutions. The same was 
observed with the “dead” 46300 Hz response, as expected since biologically relevant binding 
frequencies lie below 10 kHz (Adamson et al., 2012; Fairchild et al., 2009; Gonzales and La 
Belle, 2012; La Belle et al., 2007). A high “dead” frequency however, may become important for 
calibration purposes in a future point-of-care technology. 
 
 
 
Fig. 2. 
(a) An appended plot (N=2) of the same NE/SAM 0-10,000 pg/mL gradient used in EIS using instead the Z-t 
technique at 368 Hz. (b) A calibration curve of complex impedance as a function of NE to determine the optimal 
time point to collect data. (c) Continuous impedance measurements at two frequencies during spikes of 500 pg/mL 
(2.96 nM) NE/SAM or just PBS samples. Each Pk indicates a time at which PBS or 500 pg/mL NE/SAM was 
injected into solution. (d) This bar chart shows the N=2 average peak height at each injection time point with the 
injection artifact subtracted out (using the PBS injection data). 
 
4. Conclusions 
This work has explored the use of impedance-based electrochemical techniques for use in a 
future point-of-care technology to diagnose and quantify various severities of TBI. With 
reproducible LLD’s ranging from 8 to 98 pg/mL (47.29-579.27 pM), we have shown that the 
impedance-based electrochemical techniques are sensitive enough to detect norepinephrine in 
purified and complex media at physiologically relevant concentrations. Additionally, we have 
explored the feasibility of using the Z-t technique to reduce hardware requirements without 
sacrificing sensitivity. 
 
Future work will include efforts to reduce noise in complex media via implementation of a 
membrane over the sensor surface or encapsulating the enzyme in a mesoporous structure. Other 
efforts will focus of verifying and optimizing the Z-t results in complex media and expanding the 
use of this technique for simultaneous TBI biomarker detection. 
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